PLA2R1 and acute myeloid leukemia: Furthermore, we analyzed the PLA2R1 methylation in a patient with AML (FAB M2) following allogeneic HSCT, who had minimal residual disease (MRD) and underwent pre-emptive treatment with azacitidine to avoid haematological relapse (Additional file 5: Table S4).